Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments.

导出 LinkOut

翻译打印收藏纠错

作者： Mark A,Kroenke ^[1] ; Dohan K,Weeraratne ^[2] ; Hongjie,Deng ^[3] ; Bethlyn,Sloey ^[1] ; Raju,Subramanian ^[2] ; Benjamin,Wu ^[1] ; Michael,Serenko ^[4] ; M Benjamin,Hock ^[5]

作者单位： Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States. ^[1] Amgen Inc., Pharmacokinetics and Drug Metabolism, Thousand Oaks, CA, United States. ^[2] Amgen Inc., Global Biostatistical Sciences, Thousand Oaks, CA, United States. ^[3] Amgen Inc., Global Safety, Cambridge, MA, United States. ^[4] Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States. Electronic address: mhock@amgen.com. ^[5]

关键词 ADA impact assessment Anti-drug antibody Calcimimetic Etelcalcetide Immunogenicity Surface plasmon resonance

主题词动物(Animals);抗体(Antibodies);人类(Humans);免疫测定(Immunoassay);肽类(Peptides);兔(Rabbits);表面等离激元(Surface Plasmon Resonance)

DOI 10.1016/j.jim.2017.03.005

PMID 28274835

发布时间 2019-12-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交